Description of the drug: Vitamin D3 (cholecalciferol) - aqueous solution ()
VITAMIN D 3 (cholecalciferol) - an aqueous solution.
Synonym: Colecalciferol, Colecalciferol
Vitamins D ergocalciferol and cholecalciferol are fat soluble substances and are used in the form of oil solutions; they are also part of the coated tablets. Recently developed a water-soluble dosage form of cholecalciferol (vitamin D 3 ), convenient for oral administration and highly effective in the prevention and treatment of rickets and other pathological conditions associated with a deficiency in the body of vitamin D.
When ingested, the drug is rapidly absorbed (5 times faster than oil solutions), creates a high concentration of vitamin D in the body and has a long-lasting effect.
The therapeutic effect of the drug, as well as the action of endogenous vitamins D (ergocalciferol and cholecalciferol), is due to the regulation of calcium and phosphate metabolism. Vitamin D 3 promotes the absorption of calcium and phosphate from the intestine, regulates their participation in calcification of bone tissue, slows down the excretion of calcium and phosphorus ions from the body. Regulatory effects on the metabolism of calcium and phosphorus ions also explain other features of the drug's action: regulation of nervous excitement, muscle tone, blood coagulation, etc. (see Calcium preparations and agents for treating osteoporosis).
Apply vitamin D 3 (cholecalciferol) - an aqueous solution for the following indications: prevention and treatment of rickets; hypocalcemic tetany; hypoparathyroidism; osteomalacia and osteoporosis, including the prevention and treatment of osteoporosis associated with hormonal disorders in postmenopausal women.
Assign inwards in the form of drops.
For postnatal specific prevention of rickets in full-term healthy children, the minimum dose is 400-500 IU (1 drop) per day. This dose is used starting from 3-4 weeks of age in the autumn-winter and spring periods during the first two years of life, taking into account the conditions of existence of the child and the risk factors for developing the disease. For children at risk for rickets, 1000 IU (2 drops) are given daily at the same time. In case of preterm I, they use 400-1000 IU (1-2 drops) daily, starting from the 10-14th day of life for the first two years (excluding summer months), and with prematurity II-III degree - 1000-2000 ME ( 2-4 drops) daily in the first year of life and 500-1000 IU (1-2 drops) in the second year of life (excluding the summer months).
For the treatment of rickets, it is usually prescribed 2000-5000 ME (4-10 drops) daily for 30-45 days, after which they switch to a maintenance dose (500 ME) once a day for two years and during the winter period in the third year of life ( dose of 5000 ME is used only for pronounced bone changes). 3 months after the end of the 1st course, children from the risk group are given a repeated course of anti-relapse treatment (2000-5000 ME each) for 3-4 weeks (except for the summer months).
With proper dosing, the drug is well tolerated.